Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nuclear receptors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Nuclear receptors. Displaying page 1 of 1.
    EudraCT Number: 2016-005129-35 Sponsor Protocol Number: FENET-2016 Start Date*: 2018-02-22
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA
    Full Title: "Peptide Receptor Radionuclide Therapy (PRRT) with somatostatin analogs in tumors over-expressing somatostatin receptors"
    Medical condition: Tumors over-expressing somatostatin receptors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10014712 Endocrine neoplasms malignant and unspecified NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000983-17 Sponsor Protocol Number: MN3 Start Date*: 2008-02-20
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: Diagnostic procedure with 68Ga-labelled somatostatin analogues in tumours presumably expressing SSTR2 and/or 5 receptors, to be evaluated for treatment with the same analogues labelled with 90Y o 1...
    Medical condition: Valutation of expression of receptors SSTR2 and/or 5 in neoplastic patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022893 Investigations, imaging and histopathology procedures NEC HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006234-16 Sponsor Protocol Number: INT003 Start Date*: 2012-03-27
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refra...
    Medical condition: Patients bearing neuroendocrine tumour expressing somatostatin receptors refractory to conventional therapies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001016-51 Sponsor Protocol Number: 05-UTROGEL-01 Start Date*: 2006-02-28
    Sponsor Name:Karolinska Hospital
    Full Title: In vivo effects of transdermal Estradiol+ oral Progesterone vs oral Conjugated Equine Estrogens + MedroxyProgesteroneAcetate on normal human breast cells proliferation: a randomized comparative study
    Medical condition: Menopausal symptoms
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007965-22 Sponsor Protocol Number: IWT-TBM 0707181 Start Date*: 2009-06-04
    Sponsor Name:Nuclear Medicine UZ Gasthuisberg [...]
    1. Nuclear Medicine UZ Gasthuisberg
    2. Gastroenterology UZ Gasthuisberg
    3. Hepatology UZ Gasthuisberg
    4. General Medical Oncology UZ Gasthuisberg
    5. Radiopharmacy
    6. Radiotherapy UZ Gasthuisberg
    Full Title: Evaluating diagnostic challenges in the management of neuroendocrine tumours with peptide receptor radionuclide therapy
    Medical condition: Patients with a histological proven neuroendocrine tumour, without other curative options.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002526-23 Sponsor Protocol Number: 68GaPET-Meningioma-2013 Start Date*: 2014-02-12
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Impact of 68Ga-DOTAOTC PET for diagnosis of newly diagnosed or recurrent meningiomas
    Medical condition: Based on the finding that meningiomas express somatostatin-receptor 2 (SSTR2), PET imaging with SSTR ligands like 68Ga-DOTATOC has been proposed as a more specific method. Currently, the role of SS...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005531-28 Sponsor Protocol Number: Urso in Obese Start Date*: 2008-04-03
    Sponsor Name:Hanns-Ulrich Marschall
    Full Title: Ursodeoxycholic Acid in Morbidly Obese Patients Before Bariatric Surgery
    Medical condition: Patients with morbid obesity (MB) are investigated. MB is very frequently (90%) associated with non-alcoholic fatty liver disease (NAFLD) comprising a spectrum reaching from steatosis (NAFL) over s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029530 Non-alcoholic fatty liver LLT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001521-41 Sponsor Protocol Number: UoL001304 Start Date*: 2017-09-18
    Sponsor Name:University of Liverpool
    Full Title: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer
    Medical condition: Premenopausal ER-positive, PgR-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-003601-21 Sponsor Protocol Number: ZX-2021-FES-ESTROTIMP-4. Start Date*: 2021-09-22
    Sponsor Name:Zionexa
    Full Title: Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after a first line of treatment combining hormonal therapy
    Medical condition: Patients with metastatic breast cancer initially presenting with overexpression of estrogen receptors (ERs) and absence of overexpression of HER2, relapsing after a first therapeutic line combining...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000698-57 Sponsor Protocol Number: MDV3100-11 Start Date*: 2013-09-01
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed) IE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-024067-41 Sponsor Protocol Number: COLTONE Start Date*: 2011-04-28
    Sponsor Name:F.A.R.O. FONDAZIONE PER LE ATTIVITA' DI RICERCA IN ONCOLOGIA
    Full Title: Pilot study of sequential adjuvant chemotherapy regimen including non-pegylated Liposomal Doxorubicin (MYOCET) in combination with Cyclophosphamide and Paclitaxel in elderly patients with diagnosis...
    Medical condition: Elderly patients with diagnosis of early breast Cancer candidate to adjuvant chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005792-12 Sponsor Protocol Number: GOIRC-06-2020 Start Date*: 2022-04-05
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Medical condition: Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003767-23 Sponsor Protocol Number: EGF105884 Start Date*: 2006-07-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in S...
    Medical condition: Stage III, IVa, IVb Squamous Cell Carcinoma of the Head & Neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 01:27:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA